Atopic dermatitis (AD) is a chronic, heterogenous, inflammatory skin disorder associated
with a high skin‐related health burden, typically starting in childhood and often persisting …

Atopic dermatitis (AD) is a chronic, pruritic, inflammatory dermatosis that imposes significant
patient and population burdens. In addition to the cutaneous signs and symptoms, growing …

Summary Background The Global Burden of Disease (GBD) Study provides an annually
updated resource to study disease‐related morbidity and mortality worldwide. Objectives …

Abstract Rademikibart (CBP-201) is a next-generation human monoclonal antibody
targeting IL-4Rα, undergoing evaluation in Phase 2 clinical trials for the treatment of …

Background Atopic dermatitis is known to be common among children, but there are few
studies examining the epidemiology across the life course. In particular, there is a paucity of …

Background Evidence suggests an association between atopic eczema (AE) or psoriasis
and mental illness; however, the factors associated with mental illness are unclear …

Importance Research has highlighted associations between atopic dermatitis (AD) and
mental health conditions in adults. However, literature on the development of mental health …

Background Psoriasis and atopic eczema are common inflammatory skin diseases. Existing
research has identified increased risks of common mental disorders (anxiety, depression) in …

Biomarkers associated with the development of comorbidities in atopic dermatitis (AD)
patients have been reported, but have not yet been systematically reviewed. Seven …

Abstract IL‐4 and IL‐13 signaling via IL‐4Rα plays key roles in the pathogenesis of atopic
dermatitis (AD) and asthma. Rademikibart (formerly CBP‐201), a next‐generation human …